Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/6/2018
SIETES contiene 92380 citas

 
 
 1 a 20 de 851 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Feuerstein A. After watching Trump’s drug speech, investors poured big money into biotech funds. STAT Daily Recap 2018:4. [Ref.ID 102605]
2. Cita con resumen
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]
3. Cita con resumen
Anónimo. Comparative effectiveness of proton pump inhibitors. Therapeutics Initiative Evidence Based Drug Therapy 2016;99:1-2. [Ref.ID 100573]
5. Cita con resumen
Greene MF, Drazen JM. A new label for mifepristone. N Engl J Med 2016;374:2281-2. [Ref.ID 100400]
6. Cita con resumen
Gulland A. MSF accuses Pfizer of misleading advertising. BMJ 2016;352:i896. [Ref.ID 100060]
7. Cita con resumen
Anónimo. Two long-acting injectable antipsychotics for schizophrenia. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:152-3. [Ref.ID 99815]
8.Tiene citas relacionadas Cita con resumen
Meier F, Maas R, Sonst A, Patapovas A, Müller F, Plank-Kiegele B, Pfistermeister B, Schöffski O, Bürkle T, Dormann H. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf 2015;24:176-86. [Ref.ID 99600]
9.
Anónimo. Panobinostat (Farydak) for multiple myeloma. Med Lett Drugs Ther 2015;57:118-9. [Ref.ID 99467]
10. Cita con resumen
Avorn J. The $2.6 billion pill — Methodologic and policy considerations. N Engl J Med 2015;372:1877-9. [Ref.ID 99114]
11. Cita con resumen
Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, Birrell F, Chakravarty K, Maddison P, Heslin M, Patel A, Kingsley GH. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015;350:h1046. [Ref.ID 98857]
12. Cita con resumen
Anónimo. Gilead’s hepatitis C treatments reach $12.4B in profits during 2014. DIA Daily 2015:4 de febrero. [Ref.ID 98768]
13.Tiene citas relacionadas Cita con resumen
Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312:593-4. [Ref.ID 98450]
14.Tiene citas relacionadas Cita con resumen
Lopert R, Welch C. Costs of new treatments for hepatitis C infection. JAMA 2014;312:2168. [Ref.ID 98449]
15.Tiene citas relacionadas Cita con resumen
Green JB. Costs of new treatments for hepatitis C infection. JAMA 2014;312:2168. [Ref.ID 98448]
16. Cita con resumen
Anónimo. Study: cost to develop, bring a drug to market about $2.6B. DIA Daily 2014:19 de noviembre. [Ref.ID 98334]
18.Tiene citas relacionadas Cita con resumen
Hoofnagle JH, Sherker AH. Therapy for hepatitis C - the costs of success. N Engl J Med 2014;370:1552-3. [Ref.ID 97486]
19. Cita con resumen
Watson R. EU nations approve law to bring transparency to clinical trials. BMJ 2014;348:f7682. [Ref.ID 97170]
20. Cita con resumen
Pershing S, Enns EA, Matesic B, Owens DK, Godhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med 2014;160:18-29. [Ref.ID 97012]
Seleccionar todas
 
 1 a 20 de 851 siguiente >>